2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Clinical Procedures, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Workforce, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, LGL, Hodgkin Lymphoma, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4350 High-throughput single cell sequencing outperforms bulk sequencing for the assessment for of multiplex gene editing after transplantation

Stefan Radtke, PhD, Kyle Swing2, Carl B Worf3, Liatris Reevey4, Dnyanada Pande5, Mark Enstrom6, Greta Kanestrom7, Andrea Repele8, Roland Bruno Walter, MD, PhD, MS9, Hans-Peter Kiem, PhD10
1 Fred Hutch Cancer Center, Seattle, United States
2 Fred Hutch Cancer Center, Seattle, United States
3 Fred Hutch Cancer Center, Seattle, United States
4 Fred Hutch Cancer Center, Seattle, United States
5 Fred Hutch Cancer Center, Seattle, United States
6 Fred Hutch Cancer Center, Seattle, United States
7 Fred Hutch Cancer Center, Seattle, United States
8 Fred Hutch Cancer Center, Seattle, United States
9 Fred Hutch Cancer Center, Seattle, United States
10 Fred Hutch Cancer Center, Seattle, United States

The development of gene-editing technologies has broadened the opportunities to cure monogenic diseases. Especially the multiplexing of a therapeutic base edit with an epitope edit for the enrichment/selection of successfully gene-modified cells using either chimeric antigen receptor (CAR) T cells or antibody-drug conjugates (ADC) has recently gained popularity. Multiplex gene editing is commonly assessed in bulk cell populations from the blood and bone marrow not providing mono- and bi-allelic editing outcomes nor confirming successful editing of both targets within the same cell. Confirmation of multiplex editing requires analysis on a single cell level, a readout that is currently limited to clonally expanding CD34+ hematopoietic stem and progenitor cell (HSPCs) in colony-forming cell assays. This readout is very labor intensive, error prone, has a very low resolution, and does not provide evidence that multiplex edited HSPCs contribute to all lineages without bias.

To overcome this limitation, we established a new high-throughput single cell pipeline to assess multiplex gene editing in combination with phenotypic information on blood, marrow, and CD34+ HSPCs. Specimens from two myeloablative conditioned nonhuman primates transplanted with multiplex gene-edited CD34+ HSPCs knocked out for the cell surface marker CD33 and modified at the HBG promotor to reactivate fetal hemoglobin were analyzed. A custom target library was designed to capture editing at CD33, the CD33 pseudogene SIGLEC22P, and HBG1/2 with the ability to distinguish HBG1 and HBG2. To capture the phenotype of cells, specimens were stained with barcoded antibodies. Sequencing data for DNA targets and antibody targets were analyzed using custom code and data compared to allelic editing frequencies using traditional sequencing on bulk specimen.

Assessment of data for more than 20K individual blood and marrow cells confirmed successful capture of mono- and bi-allelic editing states for all targeted loci. Patterns of editing at the adenines within the protospacer closely mirrored the editing determined by bulk sequencing. All mature blood cell lineages were detected using barcoded antibodies and frequencies of cell types closely matched flow-cytometric data. Overlay of genotypes with phenotypic data showed reproducible patterns of mono- and bi-allelic editing across all lineages confirming unbiased contribution of gene-modified HSPCs to the blood. Quantification of cell-based editing frequencies revealed that bulk sequencing vastly underestimates the actual replacement efficiency after transplantation. Over 90% of blood cells carried a base-editor introduced edit at one of the four assessed genes confirming near full replacement of the hematopoietic system with ex vivo gene modified cells. Most importantly, animals that were considered below the therapeutic threshold for HBG editing (<20%) based on bulk sequencing data were well within the curative/therapeutic range (20-40%) assessing and overlaying mono- and bi-allelic editing states on a single cell level for HBG1 and 2.

High-throughput single cell genotyping + phenotyping provides the opportunity to analyze multiple gene-editing targets on thousands of HSPCs and mature lineages simultaneously. The ability to assess the genotype of all blood cells and especially granulocytes on a single cell level provides a novel non-invasive surrogate to closely monitor successful engraftment and long-term multilineage contribution of edited HSPCs in gene therapy patients without performing invasive marrow harvests and using minimal amounts of peripheral blood only. Target libraries can be easily adapted for other genomic loci including known or putative off-target locations providing a new way to simultaneously assess efficiency and safety of ex vivo as well as in vivo after gene therapy with high sensitivity and throughput.

Stefan Radtke, PhD: Innograft - Consultancy (Includes expert testimony); Ensoma - Consultancy (Includes expert testimony)